News | March 24, 2026
Japan okays new long-acting eye drug
It promises fewer injections for vision loss patients
It promises fewer injections for vision loss patients
Call it a major breakthrough for diagnostic imaging
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Subscribe To Our Newsletter & Stay Updated
